We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Portable PCR Molecular Analyzer Delivers Time-Critical Results in Near-Patient Setting

By LabMedica International staff writers
Posted on 24 Mar 2023
Print article
Image: The Genomadix Cube can go places where access to diagnostic testing may have previously been limited (Photo courtesy of Genomadix)
Image: The Genomadix Cube can go places where access to diagnostic testing may have previously been limited (Photo courtesy of Genomadix)

Conventional laboratory-based tests may require several days or weeks to generate results. Now, a fast, accurate, and portable DNA analyzer goes from sample to result in approximately an hour, making results more accessible.

The Genomadix Cube from Genomadix (Ottawa, Canada) is a portable molecular analyzer that employs the gold standard Polymerase Chain Reaction (PCR) technique, delivering accurate outcomes without the need for a full-service laboratory. This decentralized testing option is particularly useful for remote industries and communities where access to a complete lab is limited. The PCR molecular diagnostic instrument generates top-quality results outside of a lab setting and is capable of testing for genetic, infectious disease, and environmental targets on a sample-to-result platform.

Collected samples are placed into a disposable DNA test cartridge, which is then inserted into the analyzer. Once inside, the cartridge extracts the DNA/RNA and produces millions of copies using the PCR process. An optical system detects the amplified fluorescence, and algorithms automatically generate a test outcome. The analyzer's portability, user-friendliness, and real-time processing capabilities allow for the swift generation of critical results.

Related Links:
Genomadix 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more